OSCR
Oscar Health, Inc.
OSCR has the edge over TXG overall, supported by stronger fundamentals and lower modeled downside.
TXG
10x Genomics, Inc.
TXG offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TXG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Strong | |
| Unavailable |
TXG's cash flow is currently strong, and its revenue is stable, but its profitability is under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TXG PE Valuation
TXG has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TXG's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TXG on earnings quality, reporting a profit while its opponent remains loss making.
TXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.52 | +$0.10 |
| Q2 2026 | -$0.59 | +$0.11 |
| Q1 2026 | -$0.17 | +$1.13 |
| Q4 2025 | -$0.35 | +$1.17 |
| Q3 2025 | -$0.62 | +$0.92 |
| Q2 2025 | -$0.70 | +$1.33 |
| Q1 2025 | -$1.30 | +$0.94 |
| Q4 2024 | -$1.52 | +$0.66 |
TXG is still losing money, but far less than before: $0.52 per share over the past year, against $5.37 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TXG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TXG on profitability, with a higher operating margin.
TXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $150.7M | +1.1% |
| Q2 2026 | $151M | -13% |
| Q1 2026 | $150.8M | -2.6% |
| Q4 2025 | $166M | +0.6% |
| Q3 2025 | $149M | -1.7% |
| Q2 2025 | $172.9M | +13% |
| Q1 2025 | $154.9M | +9.8% |
| Q4 2024 | $165M | -10% |
TXG's revenue fell from its 2023 peak and has held roughly level since: $151M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11% | +11 points |
| Q2 2026 | -13% | -30 points |
| Q1 2026 | -11% | +14 points |
| Q4 2025 | -12% | +18 points |
| Q3 2025 | -22% | +5.7 points |
| Q2 2025 | 17% | +45 points |
| Q1 2025 | -25% | +18 points |
| Q4 2024 | -30% | -0.2 points |
TXG's operating margin was −11% last quarter, up 11 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TXG on cash flow, with more consistent year-over-year improvement.
TXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.9M | -65% |
| Q2 2026 | $15.4M | -4.6% |
| Q1 2026 | $24.5M | -24% |
| Q4 2025 | $39M | +$48.5M |
| Q3 2025 | $42.5M | +140% |
| Q2 2025 | $16.1M | +249% |
| Q1 2025 | $32.5M | +$51.1M |
| Q4 2024 | -$9.5M | -142% |
TXG has burned cash in most quarters: $94M over the past year, up 15% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +822K shares |
| 1 year | +4.2% | +5.3M shares |
| 3 years | +11% | +13.1M shares |
| 5 years | +18% | +19.9M shares |
| Available history | +35% | +34M shares |
TXG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TXG Net Leverage
TXG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.2 | Neutral |
| Stochastic | 28.5 | Neutral |
TXG's weekly RSI is 52 (neutral) and its Stochastic is 28 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TXG PE vs Healthcare Sector
TXG has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TXG on trend strength, trading above more of its moving averages.
TXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.7 | 20% below |
| 20 week MA | $62.6 | 5.5% below |
| 50 week MA | $38.3 | 54% above |
| 100 week MA | $25.3 | 134% above |
| 200 week MA | $31.8 | 86% above |
TXG has slipped below its 8- and 20-week averages, though it's still 86% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.
TXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.2 | $151.3 | +94% |
| 2021 | $151.3 | $146.1 | -3.5% |
| 2022 | $146.1 | $34.2 | -77% |
| 2023 | $34.2 | $56.0 | +63% |
| 2024 | $56.0 | $14.6 | -74% |
| 2025 | $14.6 | $16.5 | +13% |
| 2026 YTD | $16.5 | $59.1 | +258% |
TXG has the edge over OSCR on returns for 2026, with the stronger performance.